Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Makoto Nishio; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Benjamin J. Solomon; Alice T. Shaw; Satoshi Hashigaki; Emiko Ohki; Tiziana Usari; Jolanda Paolini; Anna Polli; Keith D. Wilner; Tony Mok

doi:10.4143/crt.2017.280

Articles

Page Path: HOME > Cancer Res Treat > Volume 50(3); 2018 > Article

Original Article Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer: Makoto Nishio, MD^1,, Dong-Wan Kim, MD, PhD², Yi-Long Wu, MD³, Kazuhiko Nakagawa, MD, PhD⁴, Benjamin J. Solomon, MB, BS, PhD⁵, Alice T. Shaw, MD, PhD⁶, Satoshi Hashigaki, MSc⁷, Emiko Ohki, PhD⁷, Tiziana Usari, BSc⁸, Jolanda Paolini, BSc⁸, Anna Polli, BS⁸, Keith D. Wilner, PhD⁹, Tony Mok, MD¹⁰; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2018;50(3):691-700.
DOI: https://doi.org/10.4143/crt.2017.280
Published online: July 6, 2017

¹Thoracic Oncology Center, The Cancer Institute Hospital of JFCR, Tokyo, Japan

²Seoul National University Hospital, Seoul, Korea

³Guangdong Lung Cancer Institute, Guangdong, China

⁴Kindai University, Osaka, Japan

⁵Peter MacCallum Cancer Centre, Melbourne, Australia

⁶Massachusetts General Hospital, Boston, MA, USA

⁷Pfizer Oncology, Tokyo, Japan

⁸Pfizer Oncology, Milan, Italy

⁹Pfizer Oncology, La Jolla, CA, USA

¹⁰State Key Laboratory of South China, Hong Kong Cancer Institute and The Chinese University of Hong Kong, Shatin, China

Correspondence: Makoto Nishio, MD Thoracic Oncology Center, The Cancer Institute Hospital of JFCR, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
Tel: 81-3-3520-0111 Fax: 81-3-3520-0141 E-mail: mnishio@jfcr.or.jp

• Received: June 10, 2017 • Accepted: July 3, 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

15,944 Views
707 Download
43 Web of Science
37 Crossref
48 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We report the safety and efficacy of crizotinib in Asian subpopulations of two global phase III trials.
Materials and Methods
This analysis evaluated previously treated and untreated patients in two randomized, open-label phase III trials of crizotinib versus chemotherapy in ALK-positive advanced NSCLC in second-line (PROFILE 1007) and first-line settings (PROFILE 1014). Efficacy and safety were analyzed by race in the intention-to-treat and “as-treated” populations for efficacy and safety endpoints, respectively.
Results
In previously treated (n=157) and untreated (n=157) Asian patients, PFS was statistically significantly longer with crizotinib versus chemotherapy (hazard ratio for PFS, 0.526; 95% confidence interval, 0.363 to 0.762; p < 0.001 and hazard ratio, 0.442; 95% confidence interval, 0.302 to 0.648; p < 0.001, respectively). Similar antitumor activity was seen in the non-Asian and overall populations. ORRs were statistically significantly higher with crizotinib versus chemotherapy in both Asian and non-Asian previously treated and untreated patients (p < 0.05). The most common treatment-emergent adverse events (any grade)with crizotinib were vision disorder, diarrhea, and nausea, which were observed at a comparable incidence across Asian and non-Asian populations, irrespective of previous treatment status. Most adverse events were mild to moderate in severity.
Conclusion
These data, currently the only analysis showing Asian and non-Asian populations in the same study, support the efficacy and safety of crizotinib in Asian patients with previously treated or untreated ALK-positive advanced NSCLC.
Key words: Asia, Carboplatin, Cisplatin, Crizotinib, Non-small cell lung carcinoma, Pemetrexed

Introduction

Approximately 3% to 5% of all patients with non-small cell lung cancer (NSCLC) harbor a rearrangement of the anaplastic lymphoma kinase (ALK) gene, resulting in an oncogene that codes for ALK fusion proteins such as echinoderm microtubule-associated protein-like 4‒ALK, which promotes tumor cell growth. The incidence of ALK-positive NSCLC is similar among Caucasian and Asian populations [1-3]. Although this subset represents only a small proportion of the overall NSCLC population, the number still translates into approximately 40,000 patients worldwide per year [4]. Crizotinib is a first-in-class, oral, small-molecule tyrosine kinase inhibitor of ALK, ROS1, and cMET kinases that was approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of patients with locally advanced or metastatic NSCLC who test positive for the ALK fusion gene, as detected by an FDA-approved test. In 2016, the FDA further approved crizotinib for patients with metastatic NSCLC whose tumors are ROS1 positive. Crizotinib also received approval in the European Union for the first-line treatment of adults with ALK-positive advanced NSCLC or in previously treated patients, as well as for the treatment of adults with ROS1-positive advanced NSCLC.

A series of clinical trials have shown and confirmed the efficacy and safety of crizotinib in patients with ALK-positive advanced NSCLC. Named the PROFILE series, these trials consist of a phase I dose-escalation study in an array of cancer indications, including ALK-positive advanced NSCLC (PROFILE 1001 [5,6]), a phase II study evaluating patients with ALK-positive advanced NSCLC (PROFILE 1005 [7]), and three phase III trials assessing crizotinib use in ALK-positive advanced NSCLC, in both second-line (PROFILE 1007 [8]) and first-line settings (PROFILE 1014 [9] and PROFILE 1029 [10]). In these studies, crizotinib has established a consistent safety profile, with the most common adverse events (AEs) of visual disturbances, gastrointestinal effects, and elevated liver aminotransferases [7-9].

In randomized trials involving patients with ALK-positive advanced NSCLC (PROFILE 1007, PROFILE 1014, and PROFILE 1029), crizotinib has demonstrated efficacy superior to that of single-agent chemotherapy with pemetrexed or docetaxel in previously treated patients [8], and to pemetrexed plus platinum chemotherapy in previously untreated multinational [9] and Asian patients [10].

Across the PROFILE series, Asian patients have been well represented, accounting for 45% and 46% of the overall population in PROFILE 1007 and PROFILE 1014, respectively, and 100% in PROFILE 1029 [8-10]. Higher objective response rates (ORRs) have been frequently reported in Asian patients than in non-Asian patients [5,11].

Data from the phase III trial in the first-line setting with only Asian patients (PROFILE 1029) have been previously presented [10]. This report focuses on the results of multinational phase III trials that included Asian and non-Asian patients, in both the second-line (PROFILE 1007) [8] and the first-line (PROFILE 1014) [9] settings, to further evaluate the efficacy and safety profile of crizotinib in the Asian population.

Materials and Methods

Data from two randomized, open-label, phase III trials comparing crizotinib with chemotherapy and ongoing at the time of the analysis (PROFILE 1007 [8] [NCT00932893] and PROFILE 1014 [9] [NCT01154140]) were analyzed. The detailed methodologies and primary results for both studies have been previously published [8,9]. Each participating center’s institutional review board or independent ethics committee approved these protocols. The studies complied with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws. All patients provided written informed consent before enrollment.

1. Study design and treatment

In PROFILE 1007, patients with ALK-positive advanced NSCLC who had progressive disease following one prior platinum-based chemotherapy regimen were randomly assigned, in a 1:1 ratio, to receive continuous oral crizotinib at a dose of 250 mg twice daily in a 3-week cycle or intravenous chemotherapy, comprising either pemetrexed 500 mg/m² or docetaxel 75 mg/m², every 3 weeks. Previously untreated patients with ALK-positive advanced NSCLC were selected for the PROFILE 1014 study and were randomized (1:1) to receive continuous oral crizotinib at a dose of 250 mg twice daily or intravenous chemotherapy of pemetrexed 500 mg/m² plus a platinum agent (either cisplatin 75 mg/m² or carboplatin, target area under the curve 5-6 mg/mL/min) administered every 3 weeks. Randomization was stratified in both studies according to Eastern Cooperative Oncology Group performance status (0 or 1 vs. 2) and presence or absence of brain metastases. Additional stratification factors included prior or no prior therapy with epidermal growth factor receptor tyrosine kinase inhibitors for PROFILE 1007 and Asian or non-Asian race for PROFILE 1014.

In both PROFILE studies:

- Treatment was continued (up to a maximum of six cycles of chemotherapy in PROFILE 1014) until disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1 per independent radiology review (IRR) was observed, development of unacceptable toxicity, death, or withdrawal of consent.

‒ Crizotinib treatment could be continued beyond disease progression per IRR at the discretion of the investigator.

‒ Patients in the chemotherapy groups who had RECIST-defined disease progression, confirmed by IRR, were allowed to cross over to receive crizotinib. In PROFILE 1007, patients who crossed over were enrolled in a separate study (PROFILE 1005). In PROFILE 1014, patients were allowed to cross over and remain in the study if they met the safety eligibility criteria for crossover.

‒ The primary endpoint was progression-free survival (PFS), as assessed by IRR, and secondary endpoints included the objective response, as assessed by IRR, and safety.

2. Assessments

Tumor assessments were to be carried out every 6 weeks during treatment until RECIST-defined disease progression was documented by IRR. In PROFILE 1007, the brain was to be included in subsequent tumor assessments if a patient had brain metastases at baseline; otherwise, the brain was only to be evaluated when clinically indicated. Repeat bone scans were required every 12 weeks only if bone metastases were present at baseline; otherwise, a repeat bone scan was required only if new bone metastases were suspected. In PROFILE 1014, brain and bone scans were performed at baseline and were repeated every 6 weeks for patients reporting brain or bone lesions at baseline or every 12 weeks to monitor for new lesions in the other patients. Patients with brain metastases were eligible if treated and neurologically stable; untreated and asymptomatic patients with brain metastases were also eligible in PROFILE 1007. In both studies, all scans were submitted for central IRR, who were unaware of the group assignments, and the data from IRR were used to determine PFS and ORR. AEs were classified and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events ver. 4.0.

3. Statistical analysis

Efficacy endpoints were analyzed in the intention-to-treat population (all randomized patients) in both studies. The Kaplan-Meier method was used to estimate time-to-event endpoints. One-sided log-rank tests (stratified for baseline factors in the overall populations of both studies and unstratified in the Asian and non-Asian subgroups) were used to compare PFS between the crizotinib and chemotherapy groups; Cox regression models were used to estimate hazard ratios (HRs; stratified in the overall populations and unstratified in the Asian and non-Asian subgroups). The ORR between crizotinib and chemotherapy groups was compared using a two-sided Pearson chi-square test. For the analyses presented here, no adjustment of the type I error was made for multiplicity. AEs were summarized in the “as-treated” population in both studies that included all patients who received at least one dose of study drug. The statistical analysis plans for both studies have been previously described [8,9].

Results

1. Patients

Baseline patient and disease characteristics were well balanced across randomized study groups and are summarized in S1 Table. In addition, the baseline characteristics in both studies were similar between Asian and non-Asian patients. A total of 314 Asian patients were randomized across the two studies (PROFILE 1007, 157/347 [45%]; PROFILE 1014, 157/343 [46%]). The majority of Asian patients were either Korean (34%) or Japanese (32%), and the majority of non-Asian patients were white (95%) (S1 Table).

2. Efficacy

Overall, PFS, as determined by IRR, was significantly longer with crizotinib than with chemotherapy in both studies (Fig. 1A and D). In previously treated Asian patients, the HR for PFS with crizotinib was 0.526 (95% confidence interval [CI], 0.363 to 0.762; p < 0.001); median PFS was 8.1 and 2.8 months in the crizotinib and chemotherapy groups, respectively (Fig. 1B). A comparable benefit was observed for PFS with crizotinib in previously treated non-Asian patients (HR, 0.447; 95% CI, 0.304 to 0.655; p < 0.001); median PFS was 7.1 months with crizotinib and 3.2 months with chemotherapy (Fig. 1C). PFS was also significantly longer with crizotinib than with chemotherapy in treatment-naïve patients, both Asian (HR, 0.442; 95% CI, 0.302 to 0.648; p < 0.001; median PFS, 13.6 and 7.0 months, respectively) and non-Asian (HR, 0.525; 95% CI, 0.363 to 0.760; p < 0.001; median PFS, 9.6 and 7.2 months, respectively) (Fig. 1E and F).

In both previously treated and untreated patients with ALK-positive advanced NSCLC, comparable efficacy of crizotinib versus chemotherapy was observed in both Asian and non-Asian patients, as well as in the overall population (Table 1). As assessed by IRR, the ORRs in the intention-to-treat populations were statistically significantly higher with crizotinib than with chemotherapy, respectively, in both previously treated (75% vs. 22%) and untreated (70% vs. 54%) Asian patients (p < 0.05). A similar effect was observed in previously treated (57% vs. 18%, respectively) and untreated (78% vs. 37%, respectively) non-Asian patients (p < 0.001) (S2 Fig.). Objective responses among crizotinib-treated patients were both rapid in onset (median time to response, up to 6 weeks; coinciding with the first tumor assessment per protocol) and durable (median duration of response, 31 and 32 weeks in previously treated patients, respectively, and 42 and 54 weeks in previously untreated patients, respectively) among Asian and non-Asian patients (Table 1).

3. Safety

In the crizotinib group, the most common treatment-emergent AEs of any cause (any grade) in previously treated or untreated Asian and non-Asian patients, respectively, were vision disorders (44%-79%), diarrhea (52%-70%), nausea (45%-66%), vomiting (33%-62%), constipation (37%-51%), elevated transaminases (25%-49%), and edema (23%-55%). In both studies, reported incidence rates of grades 1-2 AEs across all populations and treatment groups were between 37% (lowest incidence rate [previously untreated non-Asian patients in the crizotinib group]) and 53% (highest incidence rate [previously treated Asian patients in the chemotherapy group]).

Overall, the AE profiles of crizotinib among Asian pretreated and treatment-naïve patients were generally comparable with those observed in the corresponding non-Asian patients. However, AEs of elevated transaminases and decreased appetite were reported more frequently in Asian patients than in non-Asian patients treated with crizotinib or chemotherapy in both studies (Table 2). Among previously treated patients, diarrhea, vomiting, and neutropenia were more common in Asian patients treated with either crizotinib or chemotherapy than in the non-Asian population.

In PROFILE 1007, the median duration of treatment was 31 weeks with crizotinib and 12 weeks with chemotherapy. Median duration of treatment in PROFILE 1014 was 47 weeks with crizotinib and 18 weeks with chemotherapy. Overall, permanent discontinuation of crizotinib associated with treatment-related AEs occurred at a similar rate in both studies (6.4% and 4.7% for PROFILE 1007 and PROFILE 1014, respectively). Rates of permanent treatment discontinuation of crizotinib were higher among Asian than non-Asian patients in both studies (PROFILE 1007: 11.4% vs. 2.2%, respectively; PROFILE 1014: 6.5% vs. 3.2%, respectively). The AE most frequently associated with permanent treatment discontinuation of crizotinib was interstitial lung disease in 2.3% (5.1% Asian vs. 0.0% non-Asian) and 1.2% (1.3% Asian vs. 1.1% non-Asian) of patients in PROFILE 1007 and PROFILE 1014, respectively. Other AEs associated with permanent discontinuation in both studies included elevated transaminases, hepatotoxicity, and nausea (S3 and S4 Tables).

Discussion

Crizotinib has demonstrated superior efficacy over standard chemotherapy in phase III studies of previously treated and untreated patients with ALK-positive advanced NSCLC. In comparison with chemotherapy, crizotinib significantly prolonged PFS and increased ORRs. Responses in patients treated with crizotinib were generally seen within up to 6 weeks of treatment initiation, irrespective of prior treatment status, and durable [8,9].

These subgroup analyses have shown that the efficacy of crizotinib in previously treated and untreated Asian patients is consistent with that seen for non-Asian populations. Comparable PFS and ORRs for Asian and non-Asian patients have been observed in both studies, although a higher ORR was seen with crizotinib in the second-line setting among Asian patients (ORR, 75%; 95% CI, 64 to 84) than among non-Asian patients (ORR, 57%; 95% CI, 47 to 68), but the 95% CI overlapped.

The safety of crizotinib for Asian and non-Asian patients was consistent with previous publications, exhibiting a distinct AE profile compared with chemotherapy and a low incidence of permanent treatment discontinuations. The most common AEs observed with crizotinib included visual impairment, diarrhea, nausea, vomiting and constipation, elevated transaminases, and peripheral edema, which were commonly reported AEs across the Asian and non-Asian populations in both studies. However, some AEs were reported with higher frequency for Asian than non-Asian patients in both studies, as noted below.

In this subgroup analysis, AEs across both PROFILE 1007 and PROFILE 1014 were generally of low-grade severity (grades 1-2), with a similar incidence of grades 3-4 AEs for both Asian and non-Asian patients treated with crizotinib, and were associated with few permanent treatment discontinuations.

However, the incidence of selected AEs for patients treated with either crizotinib or chemotherapy was higher for the Asian population than for the non-Asian population in previously treated patients. For example, gastrointestinal events, such as diarrhea and vomiting, were observed at a higher frequency (≥ 10%) in the Asian subgroup than in the non-Asian subgroup of both treatment groups of PROFILE 1007. In contrast, the incidence of these AEs was similar in previously untreated Asian and non-Asian patients, although the incidence of constipation was higher among Asian patients in PROFILE 1014. The higher incidence of AEs among Asian patients than non-Asian patients noted in PROFILE 1007 is consistent with previous reports for crizotinib [11] and chemotherapy [12].

While patient and disease characteristics were well balanced between the Asian and non-Asian subgroups across both studies, neither PROFILE 1007 nor PROFILE 1014 was designed or powered to support inferential analyses of these subgroups.

Notwithstanding previously noted limitations, the efficacy and safety of crizotinib in Asian patients with ALK-positive advanced NSCLC were comparable to those observed in non-Asian patients, further supporting the use of crizotinib in the Asian population. These studies, currently the only trials that have included Asian and non-Asian populations in the same study, provide evidence supporting the efficacy and safety of crizotinib in Asian patients, both in the first-line setting and in previously treated patients.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (http://www.e-crt.org).

crt-2017-280-suppl1.pdf

crt-2017-280-suppl2.pdf

crt-2017-280-suppl3.pdf

crt-2017-280-suppl4.pdf

NOTES

BJS has received honoraria from and participated in advisory boards for AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche. He has also received institutional research funding from AstraZeneca, Merck, Novartis, Pfizer, and Roche and has patent/intellectual property to disclose from Biodesix. ATS has received research funding from and participated in advisory boards for Genentech, Novartis, Pfizer, and Roche. She participated in advisory boards for ARIAD, Blueprint Medicines, Daiichi Sankyo, EMD Serono, Loxo Oncology, and Taiho. EO, TU, JP, AP, and KDW are all employees of Pfizer and have stock ownership in Pfizer. TM has a company leadership role and stock ownership in Sanomics Ltd. He has received honoraria and participated in advisory boards for ACEA Biosciences, Inc., AstraZeneca, AVEO, Biodesix, BioMarin, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis Oncology, Eli Lilly and Company, GlaxoSmithKline, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, OncoGenex Pharmaceuticals Inc., Pfizer, Roche/Genentech, SFJ Pharmaceuticals, and Vertex Pharmaceuticals. He has also received honoraria from Amgen and Prime Oncology and participated in advisory boards for geneDecode Co., Ltd. He has received research funding and speakers bureau fees in the last 2 years from AstraZeneca, Boeh-ringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Merck Sharp & Dohme, Novartis, Pfizer, and Roche. He has received speakers bureau fees from Amgen, Eli Lilly and Company, GlaxoSmithKline, Janssen, and Prime Oncology and received research funding from ARIAD Pharmaceuticals, Inc. and SFJ Pharmaceuticals. The remaining authors have no conflicts of interest to disclose.

Acknowledgements

This work was supported by Pfizer Inc. We would like to thank all of the participating patients and their families, as well as the investigators, research nurses, study coordinators, and operations staff, along with Hironori Kikkawa (Pfizer, Japan) for providing the analyses for this publication. The studies included in this analysis were sponsored by Pfizer Inc. Medical writing and editorial support were provided by Jade Drummond and Simon Lancaster of inScience Communications, Springer Healthcare (Chester, UK), and were funded by Pfizer Inc.

Fig. 1.

Progression-free survival by independent radiology review for all previously treated patients (A); previously treated Asian patients (B); previously treated non-Asian patients (C); all previously untreated patients (D); previously untreated Asian patients (E); and previously untreated non-Asian patients (F). mPFS, median progression-free survival; CI, confidence interval; HR, hazard ratio; ECOG PS, Eastern Cooperative Oncology Group performance status. ^a)Based on the Brookmeyer and Crowley method, ^b)Based on the Cox proportional hazards model (assuming proportional hazards, an HR < 1 indicates a reduction in hazard rate in favor of crizotinib; an HR > 1 indicates a reduction in hazard rate in favor of chemotherapy), ^c)One-sided p-value from the log-rank test stratified by ECOG PS, brain metastases, and prior epidermal growth factor receptor tyrosine kinase inhibitor treatment (PROFILE 1007) or by ECOG PS, race, and brain metastases (PROFILE 1014), ^d)One-sided p-value from the unstratified log-rank test.

Table 1.

Response to treatment in Asian and non-Asian patients

	Asian patients		Non-Asian patients		All patients
	Crizotinib	Chemotherapy^a)	Crizotinib	Chemotherapy^a)	Crizotinib	Chemotherapy^a)
PROFILE 1007	n=79	n=78	n=94	n=96	n=173	n=174
Type of response
Complete response	1 (1)	0	0	0	1 (1)	0
Partial response	58 (73)	17 (22)	54 (57)	17 (18)	112 (65)	34 (20)
Stable disease	10 (13)	28 (36)	22 (23)	35 (37)	32 (19)	63 (36)
Progressive disease	6 (8)	29 (37)	5 (5)	31 (32)	11 (6)	60 (35)
Not evaluable^b)	4 (5)	4 (5)	13 (14)	13 (14)	17 (10)	17 (10)
Objective response rate (%)	75	22	57	18	65	20
95% CI^c)	64-84	13-33	47-68	11-27	58-72	14-26
p-value^d)	< 0.001		< 0.001		< 0.001
Duration of response (wk)^e)
Median	31.0	24.4	32.1	19.9	32.1	24.4
95% CI^f)	23.1-42.3	15.0-NR	24.4-51.3	12.1-43.6	26.4-42.3	15.0-36.0
Time to response (wk)
Median	6.3	19	6.4	11.9	6.3	12.6
Range	5.3-18.1	5.0-37.0	4.4-48.4	5.1-37.1	4.4-48.4	5.0-37.1
PROFILE 1014	n=77	n=80	n=95	n=91	n=172	n=171
Type of response
Complete response	1 (1)	1 (1)	2 (2)	1 (1)	3 (2)	2 (1)
Partial response	53 (69)	42 (53)	72 (76)	33 (36)	125 (73)	75 (44)
Stable disease	16 (21)	27 (34)	13 (14)	36 (40)	29 (17)	63 (37)
Progressive disease	5 (7)	8 (10)	3 (3)	13 (14)	8 (5)	21 (12)
Not evaluable^b)	2 (3)	2 (3)	5 (5)	8 (9)	7 (4)	10 (6)
Objective response rate (%)	70	54	78	37	74	45
95% CI^c)	59-80	42-65	68-86	27-48	67-81	37-53
p-value^d)	0.048		< 0.001		< 0.001
Duration of response (wk)^e)
Median	54.3	18.6	42.0	24.3	49.0	22.9
95% CI^f)	42.1-NR	12.3-24.1	30.6-58.9	19.3-25.9	35.1-60.0	18.0-25.1
Time to response (wk)
Median	6.1	12.1	6.3	12.1	6.1	12.1
Range	5.1-29.6	5.3-36.7	2.7-41.4	5.1-25.0	2.7-41.4	5.1-36.7

Values are presented as number (%) unless otherwise indicated. CI, confidence interval; NR, not reported.

^a) PROFILE 1007: pemetrexed or docetaxel; PROFILE 1014: pemetrexed plus cisplatin or carboplatin,

^b) Could not be evaluated, including early death and indeterminate,

^c) Using exact method based on F-distribution,

^d) p-value is from a two-sided Pearson chi-square test,

^e) Kaplan-Meier estimate of duration of response,

^f) Based on the Brookmeyer and Crowley method.

Table 2.

Treatment-emergent AEs of any cause occurring in ≥ 20%^a) of patients in the overall crizotinib group

Adverse event	Asian patients				Non-Asian patients				All patients
	Crizotinib		Chemotherapy		Crizotinib		Chemotherapy		Crizotinib		Chemotherapy
	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4
PROFILE 1007	n=79		n=77		n=93		n=94		n=172		n=171
Any adverse event	100	47	99	39	100	42	98	45	100	44	98	42
Vision disorder^b)	79	0	14	0	44	0	5	0	60	0	9	0
Diarrhea	70	0	29	1	52	0	12	0	60	0	19	1
Nausea	66	1	39	0	45	1	36	1	55	1	37	1
Vomiting	62	1	26	0	33	1	11	0	47	1	18	0
Constipation	48	4	26	0	38	1	20	0	42	2	23	0
Elevated transaminases^b)	46	20	21	3	32	12	10	2	38	16	15	2
ALT increased^b)	44	18	16	3	29	9	9	2	36	13	12	2
Edema^b)	23	0	17	0	39	0	15	0	31	0	16	0
Decreased appetite	41	3	40	3	16	2	15	1	27	2	26	2
Fatigue	39	3	35	1	16	2	32	6	27	2	33	4
Neutropenia^b)	38	19	27	22	18	9	19	17	27	13	23	19
Dysgeusia	41	0	14	0	13	0	5	0	26	0	9	0
AST increased^b)	33	10	13	1	20	1	6	0	26	5	9	1
Upper respiratory tract infection^b)	32	0	13	0	20	0	13	1	26	0	13	1
Dizziness^b)	33	1	9	0	12	0	7	0	22	1	8	0
PROFILE 1014	n=77		n=80		n=94		n=89		n=171		n=169
Any adverse event	100	44	99	49	99	48	100	54	99	46	99	52
Vision disorder^b)	66	0	9	0	76	1	10	0	71	1	10	0
Diarrhea	61	0	11	0	62	4	15	1	61	2	13	1
Nausea	52	0	60	1	59	2	57	2	56	1	59	2
Edema^b)	40	1	10	0	55	0	15	1	49	1	12	1
Vomiting	47	1	33	3	45	2	38	3	46	2	36	3
Constipation	51	0	28	0	37	3	33	0	43	2	30	0
Elevated transaminases^b)	49	20	19	3	25	10	8	2	36	14	13	2
Upper respiratory tract infection^b)	46	0	13	1	21	0	12	0	32	0	12	1
Decreased appetite	43	5	48	1	19	0	21	0	30	2	34	1
Fatigue	34	3	39	1	25	3	38	3	29	3	39	2
Dysgeusia	30	0	4	0	23	0	7	0	26	0	5	0
Abdominal pain^b)	26	0	15	0	27	0	9	0	26	0	12	0
Cough^b)	23	0	19	0	22	0	20	0	23	0	20	0
Headache	26	1	11	0	18	1	18	0	22	1	15	0
Neutropenia^b)	21	10	30	13	21	12	30	18	21	11	30	15
Neuropathy^b)	20	0	26	0	21	2	19	0	21	1	23	0

Values are presented as percentages. ALT, alanine aminotransferase; AST, aspartate aminotransferase.

^a) In decreasing order of frequency in the overall crizotinib group,

^b) This item comprised a cluster of adverse events that may represent similar clinical symptoms or syndromes, listed in S4 Table.

REFERENCES

1. Grande E, Bolos MV, Arriola E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther. 2011;10:569–79. Article PubMed
2. Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev. 2014;40:300–6. Article PubMed
3. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247–53. Article PubMed PMC
4. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31:1105–11. Article PubMed PMC
5. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011–9. Article PubMed PMC
6. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703. Article PubMed PMC
7. Kim D, Ahn M, Yang P, Liu X, De Pas T, Crino L, et al. Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer. Ann Oncol. 2012;23:402.Article
8. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94. Article PubMed
9. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77. Article PubMed
10. Lu S, Mok T, Lu Y, Zhou J, Shi Y, Sriuranpong V, et al. Phase 3 study of first-line crizotinib vs pemetrexed-cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol. 2016;34(15 Suppl):Abstr.Article
11. Ou SH, Salgia R, Clark J, Kwak EL, Camidge DR, Maki R, et al. Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies. J Thorac Oncol. 2010;5:S382.
12. Park K, Kim JH, Cho EK, Kang JH, Shih JY, Zimmermann AH, et al. East Asian subgroup analysis of a randomized, double-blind, phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy (REVEL). Cancer Res Treat. 2016;48:1177–86. Article PubMed PMC PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Inhalable iron redox cycling powered nanoreactor for amplified ferroptosis-apoptosis synergetic therapy of lung cancer
Linjing Wu, Wenhao Wang, Mengqin Guo, Fangqin Fu, Wenhua Wang, Tszching Sung, Meihong Zhang, Ziqiao Zhong, Chuanbin Wu, Xin Pan, Zhengwei Huang
Nano Research.2024; 17(6): 5435. CrossRef
Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
Akhil Kapoor, Vanita Noronha, Vijay Patil, Nandini Menon, Ravindra Nandhana, Amit Kumar, Abhishek Mahajan, Amit Janu, Rajiv Kumar, Kumar Prabhash
South Asian Journal of Cancer.2023; 12(02): 179. CrossRef
Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
Byoung Chul Cho, Dong-Wan Kim, Ullas Batra, Keunchil Park, Sang-We Kim, Cheng-Ta Yang, Pei-Jye Voon, Virote Sriuranpong, K. Govind Babu, Khalid Amin, Yingbo Wang, Paramita Sen, Khemaies Slimane, Sarayut Geater
Cancer Research and Treatment.2023; 55(1): 83. CrossRef
Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
Xiangming Zhang, Kai Ni, Huijun Chen
OncoTargets and Therapy.2023; Volume 16: 87. CrossRef
A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
Bei Zheng, Hong Jiang, Wenjuan Yang, Ying Li, Bingqing Liang, Jun Zhu, Nanmei Chen, Miao Chen, Meiling Zhang
Cancer Medicine.2023; 12(15): 15983. CrossRef
Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review
Fabien Moinard-Butot, Simon Nannini, Cathie Fischbach, Safa Abdallahoui, Martin Demarchi, Thierry Petit, Laura Bender, Roland Schott
Cancers.2023; 15(20): 4940. CrossRef
Dual peptides-modified cationic liposomes for enhanced Lung cancer gene therapy by a gap junction regulating strategy
Ziyu Zhao, Wenhao Wang, Guanlin Wang, Zhengwei Huang, Liping Zhou, Li Lin, Yueling Ou, Wanzhen Huang, Xuejuan Zhang, Chuanbin Wu, Liang Tao, Qin Wang
Journal of Nanobiotechnology.2023;[Epub] CrossRef
Performance of Japanese patients in registrational studies
Yasushi Goto, Sayaka Arakawa, Masayuki Shirasawa, Ryoko Higashiyama, Keisuke Baba, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
Japanese Journal of Clinical Oncology.2022; 52(1): 53. CrossRef
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
Laird B Cameron, Nadia Hitchen, Elias Chandran, Tessa Morris, Renée Manser, Benjamin J Solomon, Vanessa Jordan
Cochrane Database of Systematic Reviews.2022;[Epub] CrossRef
Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma
Kai Chen, Yingnan Si, Jia-Shiung Guan, Zhuoxin Zhou, Seulhee Kim, Taehyun Kim, Liang Shan, Christopher D. Willey, Lufang Zhou, Xiaoguang Liu
Biomedicines.2022; 10(1): 130. CrossRef
The application of radiomics in predicting gene mutations in cancer
Yana Qi, Tingting Zhao, Mingyong Han
European Radiology.2022; 32(6): 4014. CrossRef
Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
Alexis Cortot, Xiuning Le, Egbert Smit, Santiago Viteri, Terufumi Kato, Hiroshi Sakai, Keunchil Park, D. Ross Camidge, Karin Berghoff, Soetkin Vlassak, Paul K. Paik
Clinical Lung Cancer.2022; 23(3): 195. CrossRef
Role ofSTK11inALK‑positive non‑small cell lung cancer (Review)
Wen Zhou, Lu-Da Yan, Zhi-Qiong Yu, Na Li, Yong-Hua Yang, Meng Wang, Yuan-Yuan Chen, Meng-Xia Mao, Xiao-Chun Peng, Jun Cai
Oncology Letters.2022;[Epub] CrossRef
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
Myung J. Ahn, Hye R. Kim, James C.H. Yang, Ji-Yu Han, Jacky Yu-Chung. Li, Maximilian J. Hochmair, Gee-Chen Chang, Angelo Delmonte, Ki H. Lee, Rosario G. Campelo, Cesare Gridelli, Alexander I. Spira, Raffaele Califano, Frank Griesinger, Sharmistha Ghosh, E
Clinical Lung Cancer.2022; 23(8): 720. CrossRef
Secondary mutant ALK-I1171s in pituitary metastases from a patient with ALK fusion-positive advanced lung adenocarcinoma: A case report and literature review
Dan Han, Kewei Zhao, Qin Yang, Liling Zhang, Shihong Fei
Frontiers in Oncology.2022;[Epub] CrossRef
Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
Mei-ting Chen, Xiao-hong Fu, He Huang, Zhao Wang, Xiao-jie Fang, Yu-Yi Yao, Quan-Guang Ren, Ze-geng Chen, Tong-yu Lin
Leukemia & Lymphoma.2021; 62(3): 571. CrossRef
Breakthrough in targeted therapy for non-small cell lung cancer
Zhencong Ye, Yongmei Huang, Jianhao Ke, Xiao Zhu, Shuilong Leng, Hui Luo
Biomedicine & Pharmacotherapy.2021; 133: 111079. CrossRef
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
Daniel S.W. Tan, Sarayut Geater, Chong-Jen Yu, Chun-Ming Tsai, Te-Chun Hsia, Jun Chen, Meng-Chih Lin, You Lu, Virote Sriuranpong, Cheng-Ta Yang, Paramita Sen, Fabrice Branle, Michael Shi, Yi-Long Wu
JTO Clinical and Research Reports.2021; 2(3): 100131. CrossRef
Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group
Wenbin Li, Jing Zhang, Zhijie Wang, Lin Li, Jie Ma, Xiaoyang Zhou, Jie Wang, Zhiyong Liang, Jianming Ying
Journal of the National Cancer Center.2021; 1(4): 123. CrossRef
Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study
Fenge Jiang, Congcong Wang, Ping Yang, Ping Sun, Jiannan Liu
World Journal of Surgical Oncology.2021;[Epub] CrossRef
Genetic Analysis of Pediatric Pancreatoblastoma
Zhengzheng Wang, Xiaoting Li, Qingjun Li, Jinxue Zhou
Pancreas.2021; 50(10): 1445. CrossRef
Treatment of advanced non-small-cell lung cancer
Kumar Prabhash, Amish Vora, Sewanti Limaye, Tarini Prasad Sahoo, Ullas Batra, Shekhar Patil, Vijay M. Patil, Vanita Noronha, Bharat Bhosale, Nirmal Vivek Raut, Narayanankutty Warrier, Bharat Vaswani, Govind Babu, Adwaita Gore, Nitesh Rohatgi, Shailesh Bon
Cancer Research, Statistics, and Treatment.2021; 4(2): 279. CrossRef
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi
The Lancet Respiratory Medicine.2020; 8(1): 45. CrossRef
Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients
Lan Song, Zhenchen Zhu, Li Mao, Xiuli Li, Wei Han, Huayang Du, Huanwen Wu, Wei Song, Zhengyu Jin
Frontiers in Oncology.2020;[Epub] CrossRef
Renal complication of crizotinib: Crizotinib-associated complex renal cyst
Warissara Jutidamrongphan, Pimporn Puttawibul
The ASEAN Journal of Radiology.2020; : 44. CrossRef
A Unique Case of a High-Grade Neuroepithelial Tumor With EML4-ALK Fusion in a Five-Month-Old
Oliver D Mrowczynski, Russell Payne, Cunfeng Pu, Robert Greiner, Elias Rizk
Cureus.2020;[Epub] CrossRef
Histomorphologic features of lung adenocarcinomas exhibiting ALK gene rearrangement
Daniel S. Grosser, Haiying Zhang
Baylor University Medical Center Proceedings.2019; 32(2): 206. CrossRef
ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib
Ye Qiu, Bixun Li, Yihong Zhang, Xiaoyun Guo, Chunzhi Xiang, Congshui Wang, Yang Lu, Shuang Ren, Juan Zhao
Medicine.2019; 98(11): e14826. CrossRef
Emerging therapies for non-small cell lung cancer
Chao Zhang, Natasha B. Leighl, Yi-Long Wu, Wen-Zhao Zhong
Journal of Hematology & Oncology.2019;[Epub] CrossRef
De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
Jing-Wen Li, Shu-Hui Cao, Jian-Lin Xu, Hua Zhong
Cancer Biology & Therapy.2019; 20(9): 1183. CrossRef
Incidence and risk of fatigue in cancer patients treated with MET inhibitors
Hongxuan Tong, Yutian Zhu, Yihua Liu
Medicine.2019; 98(22): e15522. CrossRef
Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies
Xing Chang, Zi Liu, Shuai Man, Annie Roys, Zengqiang Li, Daiying Zuo, Yingliang Wu
RSC Advances.2019; 9(31): 17921. CrossRef
Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
Shih‐Hao Huang, Allen Chung‐Cheng Huang, Chin‐Chou Wang, Wen‐Chen Chang, Chien‐Ying Liu, Stelios Pavlidis, Ho‐Wen Ko, Fu‐Tsai Chung, Ping‐Chih Hsu, Yi‐Ke Guo, Chih‐Hsi Scott Kuo, Cheng‐Ta Yang
Thoracic Cancer.2019; 10(12): 2274. CrossRef
Erastin/sorafenib induces cisplatin‑resistant non‑small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway
Yu Li, Hengyi Yan, Xiaoman Xu, Hongbo Liu, Cen Wu, Li Zhao
Oncology Letters.2019;[Epub] CrossRef
Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1
Yan Yang, Caiyu Jiang, Yang Yang, Lu Guo, Jiang Huang, Xingren Liu, Chi Wu, Jun Zou
Biochemical and Biophysical Research Communications.2018; 497(4): 1003. CrossRef
Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices
Claudio Martín, Andrés F. Cardona, Zyanya Lucia Zatarain-Barrón, Alejandro Ruiz-Patiño, Omar Castillo, George Oblitas, Luis Corrales, Lorena Lupinacci, María Angelina Pérez, Leonardo Rojas, Lisde González, Luis Chirinos, Carlos Ortíz, Mauricio Lema, Carlo
Oncology.2018; 94(5): 297. CrossRef
CRISPR therapeutic tools for complex genetic disorders and cancer (Review)
Stella Baliou, Maria Adamaki, Anthony Kyriakopoulos, Demetrios Spandidos, Michalis Panagiotidis, Ioannis Christodoulou, Vassilis Zoumpourlis
International Journal of Oncology.2018;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Cancer Res Treat. 2018;50(3):691-700. Published online July 6, 2017

DOI: https://doi.org/10.4143/crt.2017.280

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Fig. 1. Progression-free survival by independent radiology review for all previously treated patients (A); previously treated Asian patients (B); previously treated non-Asian patients (C); all previously untreated patients (D); previously untreated Asian patients (E); and previously untreated non-Asian patients (F). mPFS, median progression-free survival; CI, confidence interval; HR, hazard ratio; ECOG PS, Eastern Cooperative Oncology Group performance status. a)Based on the Brookmeyer and Crowley method, b)Based on the Cox proportional hazards model (assuming proportional hazards, an HR < 1 indicates a reduction in hazard rate in favor of crizotinib; an HR > 1 indicates a reduction in hazard rate in favor of chemotherapy), c)One-sided p-value from the log-rank test stratified by ECOG PS, brain metastases, and prior epidermal growth factor receptor tyrosine kinase inhibitor treatment (PROFILE 1007) or by ECOG PS, race, and brain metastases (PROFILE 1014), d)One-sided p-value from the unstratified log-rank test.

Fig. 1.

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

	Asian patients		Non-Asian patients		All patients
	Crizotinib	Chemotherapy^a)	Crizotinib	Chemotherapy^a)	Crizotinib	Chemotherapy^a)
PROFILE 1007	n=79	n=78	n=94	n=96	n=173	n=174
Type of response
Complete response	1 (1)	0	0	0	1 (1)	0
Partial response	58 (73)	17 (22)	54 (57)	17 (18)	112 (65)	34 (20)
Stable disease	10 (13)	28 (36)	22 (23)	35 (37)	32 (19)	63 (36)
Progressive disease	6 (8)	29 (37)	5 (5)	31 (32)	11 (6)	60 (35)
Not evaluable^b)	4 (5)	4 (5)	13 (14)	13 (14)	17 (10)	17 (10)
Objective response rate (%)	75	22	57	18	65	20
95% CI^c)	64-84	13-33	47-68	11-27	58-72	14-26
p-value^d)	< 0.001		< 0.001		< 0.001
Duration of response (wk)^e)
Median	31.0	24.4	32.1	19.9	32.1	24.4
95% CI^f)	23.1-42.3	15.0-NR	24.4-51.3	12.1-43.6	26.4-42.3	15.0-36.0
Time to response (wk)
Median	6.3	19	6.4	11.9	6.3	12.6
Range	5.3-18.1	5.0-37.0	4.4-48.4	5.1-37.1	4.4-48.4	5.0-37.1
PROFILE 1014	n=77	n=80	n=95	n=91	n=172	n=171
Type of response
Complete response	1 (1)	1 (1)	2 (2)	1 (1)	3 (2)	2 (1)
Partial response	53 (69)	42 (53)	72 (76)	33 (36)	125 (73)	75 (44)
Stable disease	16 (21)	27 (34)	13 (14)	36 (40)	29 (17)	63 (37)
Progressive disease	5 (7)	8 (10)	3 (3)	13 (14)	8 (5)	21 (12)
Not evaluable^b)	2 (3)	2 (3)	5 (5)	8 (9)	7 (4)	10 (6)
Objective response rate (%)	70	54	78	37	74	45
95% CI^c)	59-80	42-65	68-86	27-48	67-81	37-53
p-value^d)	0.048		< 0.001		< 0.001
Duration of response (wk)^e)
Median	54.3	18.6	42.0	24.3	49.0	22.9
95% CI^f)	42.1-NR	12.3-24.1	30.6-58.9	19.3-25.9	35.1-60.0	18.0-25.1
Time to response (wk)
Median	6.1	12.1	6.3	12.1	6.1	12.1
Range	5.1-29.6	5.3-36.7	2.7-41.4	5.1-25.0	2.7-41.4	5.1-36.7

Adverse event	Asian patients				Non-Asian patients				All patients
	Crizotinib		Chemotherapy		Crizotinib		Chemotherapy		Crizotinib		Chemotherapy
	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4
PROFILE 1007	n=79		n=77		n=93		n=94		n=172		n=171
Any adverse event	100	47	99	39	100	42	98	45	100	44	98	42
Vision disorder^b)	79	0	14	0	44	0	5	0	60	0	9	0
Diarrhea	70	0	29	1	52	0	12	0	60	0	19	1
Nausea	66	1	39	0	45	1	36	1	55	1	37	1
Vomiting	62	1	26	0	33	1	11	0	47	1	18	0
Constipation	48	4	26	0	38	1	20	0	42	2	23	0
Elevated transaminases^b)	46	20	21	3	32	12	10	2	38	16	15	2
ALT increased^b)	44	18	16	3	29	9	9	2	36	13	12	2
Edema^b)	23	0	17	0	39	0	15	0	31	0	16	0
Decreased appetite	41	3	40	3	16	2	15	1	27	2	26	2
Fatigue	39	3	35	1	16	2	32	6	27	2	33	4
Neutropenia^b)	38	19	27	22	18	9	19	17	27	13	23	19
Dysgeusia	41	0	14	0	13	0	5	0	26	0	9	0
AST increased^b)	33	10	13	1	20	1	6	0	26	5	9	1
Upper respiratory tract infection^b)	32	0	13	0	20	0	13	1	26	0	13	1
Dizziness^b)	33	1	9	0	12	0	7	0	22	1	8	0
PROFILE 1014	n=77		n=80		n=94		n=89		n=171		n=169
Any adverse event	100	44	99	49	99	48	100	54	99	46	99	52
Vision disorder^b)	66	0	9	0	76	1	10	0	71	1	10	0
Diarrhea	61	0	11	0	62	4	15	1	61	2	13	1
Nausea	52	0	60	1	59	2	57	2	56	1	59	2
Edema^b)	40	1	10	0	55	0	15	1	49	1	12	1
Vomiting	47	1	33	3	45	2	38	3	46	2	36	3
Constipation	51	0	28	0	37	3	33	0	43	2	30	0
Elevated transaminases^b)	49	20	19	3	25	10	8	2	36	14	13	2
Upper respiratory tract infection^b)	46	0	13	1	21	0	12	0	32	0	12	1
Decreased appetite	43	5	48	1	19	0	21	0	30	2	34	1
Fatigue	34	3	39	1	25	3	38	3	29	3	39	2
Dysgeusia	30	0	4	0	23	0	7	0	26	0	5	0
Abdominal pain^b)	26	0	15	0	27	0	9	0	26	0	12	0
Cough^b)	23	0	19	0	22	0	20	0	23	0	20	0
Headache	26	1	11	0	18	1	18	0	22	1	15	0
Neutropenia^b)	21	10	30	13	21	12	30	18	21	11	30	15
Neuropathy^b)	20	0	26	0	21	2	19	0	21	1	23	0

Table 1. Response to treatment in Asian and non-Asian patients

Values are presented as number (%) unless otherwise indicated. CI, confidence interval; NR, not reported.

PROFILE 1007: pemetrexed or docetaxel; PROFILE 1014: pemetrexed plus cisplatin or carboplatin,

Could not be evaluated, including early death and indeterminate,

Using exact method based on F-distribution,

p-value is from a two-sided Pearson chi-square test,

Kaplan-Meier estimate of duration of response,

Based on the Brookmeyer and Crowley method.

Table 2. Treatment-emergent AEs of any cause occurring in ≥ 20%a) of patients in the overall crizotinib group

Values are presented as percentages. ALT, alanine aminotransferase; AST, aspartate aminotransferase.

In decreasing order of frequency in the overall crizotinib group,

This item comprised a cluster of adverse events that may represent similar clinical symptoms or syndromes, listed in S4 Table.